Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Wichita
mi
from
Wichita, KA
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Ann Arbor Regional
mi
from
Ann Arbor, MI
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Ann Arbor Regional
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Duluth
mi
from
Duluth, MN
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
Quain & Ramstad Clinic, P.C.
mi
from
Bismarck, ND
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
Quain & Ramstad Clinic, P.C.
mi
from
Bismarck, ND
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Geisinger Clinical and Medical Center
mi
from
Danville, PA
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Geisinger Clinical and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated:  7/13/2016
Saskatchewan Cancer Agency
mi
from
Regina,
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Status: Enrolling
Updated: 7/13/2016
Saskatchewan Cancer Agency
mi
from
Regina,
Click here to add this to my saved trials
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
Status: Enrolling
Updated:  7/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
Status: Enrolling
Updated: 7/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant
Status: Enrolling
Updated:  7/13/2016
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant
Status: Enrolling
Updated: 7/13/2016
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant
Status: Enrolling
Updated:  7/13/2016
Royal Women's Hospital
mi
from
Carlton,
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant
Status: Enrolling
Updated: 7/13/2016
Royal Women's Hospital
mi
from
Carlton,
Click here to add this to my saved trials
Computer-Assisted Counseling in Helping African American Smokers Stop Smoking
Treatment of Nicotine Dependence Among African Americans
Status: Enrolling
Updated:  7/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Computer-Assisted Counseling in Helping African American Smokers Stop Smoking
Treatment of Nicotine Dependence Among African Americans
Status: Enrolling
Updated: 7/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Single Subject Neratinib in Bladder Cancer (NRR)
Single Subject Neratinib in Bladder Cancer
Status: Enrolling
Updated:  7/13/2016
North Carolina Cancer Hospital (UNC)
mi
from
Chapel Hill, NC
Single Subject Neratinib in Bladder Cancer (NRR)
Single Subject Neratinib in Bladder Cancer
Status: Enrolling
Updated: 7/13/2016
North Carolina Cancer Hospital (UNC)
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Delayed-Immediate Breast Reconstruction
Delayed-Immediate Breast Reconstruction
Status: Enrolling
Updated:  7/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Delayed-Immediate Breast Reconstruction
Delayed-Immediate Breast Reconstruction
Status: Enrolling
Updated: 7/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated:  7/14/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated: 7/14/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Delayed-Delayed Breast Reconstruction
A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients With Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy
Status: Enrolling
Updated:  7/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Delayed-Delayed Breast Reconstruction
A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients With Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy
Status: Enrolling
Updated: 7/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/14/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/14/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/14/2016
Clinical Research Facility
mi
from
Boston, MA
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/14/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/14/2016
Clinical Research Facility
mi
from
St. Louis, MO
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/14/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/14/2016
Clinical Research Facility
mi
from
Houston, TX
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/14/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/14/2016
Research Site
mi
from
Villejuif Cedex,
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/14/2016
Research Site
mi
from
Villejuif Cedex,
Click here to add this to my saved trials
Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients
Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer
Status: Enrolling
Updated:  7/14/2016
University of Virginia
mi
from
Charlottesville, VA
Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients
Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer
Status: Enrolling
Updated: 7/14/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
A Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  7/14/2016
UCLA
mi
from
Los Angeles, CA
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
A Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 7/14/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Message: Study of Patients' Perception of Physician's Compassion
A Trial on Patient's Evaluation of a Physician Conveying Two Different Messages
Status: Enrolling
Updated:  7/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Message: Study of Patients' Perception of Physician's Compassion
A Trial on Patient's Evaluation of a Physician Conveying Two Different Messages
Status: Enrolling
Updated: 7/14/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine
Status: Enrolling
Updated:  7/18/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine
Status: Enrolling
Updated: 7/18/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
San Francisco, CA
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
New Brunswick, NJ
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
Dallas, TX
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
Houston, TX
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
Seattle, WA
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated:  7/18/2016
GSK Investigational Site
mi
from
Amsterdam,
Dose-Escalation Study of GSK2126458
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Status: Enrolling
Updated: 7/18/2016
GSK Investigational Site
mi
from
Amsterdam,
Click here to add this to my saved trials
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  7/18/2016
Clinical Research Facility
mi
from
St. Louis, MO
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 7/18/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  7/18/2016
Clinical Research Facility
mi
from
Buffalo, NY
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 7/18/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  7/18/2016
Clinical Research Facility
mi
from
Cleveland, OH
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 7/18/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  7/18/2016
mi
from
Caen Cedex,
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 7/18/2016
mi
from
Caen Cedex,
Click here to add this to my saved trials
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination
Status: Enrolling
Updated:  7/18/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination
Status: Enrolling
Updated: 7/18/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Diagnostic Study for Lung Cancer Detection Test
Clinical Study of BioView Target -FISH Lung Cancer Detection Test
Status: Enrolling
Updated:  7/18/2016
VA Greater Los Angeles Health System
mi
from
Los Angeles, CA
Diagnostic Study for Lung Cancer Detection Test
Clinical Study of BioView Target -FISH Lung Cancer Detection Test
Status: Enrolling
Updated: 7/18/2016
VA Greater Los Angeles Health System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Diagnostic Study for Lung Cancer Detection Test
Clinical Study of BioView Target -FISH Lung Cancer Detection Test
Status: Enrolling
Updated:  7/18/2016
Frederick Memorial Hospital, Regional Cancer Center
mi
from
Frederick, MD
Diagnostic Study for Lung Cancer Detection Test
Clinical Study of BioView Target -FISH Lung Cancer Detection Test
Status: Enrolling
Updated: 7/18/2016
Frederick Memorial Hospital, Regional Cancer Center
mi
from
Frederick, MD
Click here to add this to my saved trials
Diagnostic Study for Lung Cancer Detection Test
Clinical Study of BioView Target -FISH Lung Cancer Detection Test
Status: Enrolling
Updated:  7/18/2016
St. Luke's Hospital
mi
from
Bethlehem, PA
Diagnostic Study for Lung Cancer Detection Test
Clinical Study of BioView Target -FISH Lung Cancer Detection Test
Status: Enrolling
Updated: 7/18/2016
St. Luke's Hospital
mi
from
Bethlehem, PA
Click here to add this to my saved trials